日报更新时间：07-02 06:53
周报更新时间：01-23 11:54
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
中文名称：依特钠
英文名称：AEterna Zentaris
行业：医疗
简介：Aeterna Zentaris Inc.于1990年9月12日 ，在Canada Business Corporations Act名下成立，并继续受其管理
电话：1-843-9003211,1-843-9003223
Aeterna Zentaris Inc. 是一家开发肿瘤治疗及内分泌疾病治疗药物的生物制药公司，依特钠公司旗下产品有： MACRILEN——用于生长激素缺乏症，同时增加治疗诱发癌症恶病质，目前处于IIa临床试验阶段； ZoptEC——用于子宫内膜癌，目前处于治疗复发或转移性子宫内膜癌III期临床试验阶段； AEZS-120——重组口腔肿瘤疫苗，目前处于临床前阶段； PI3K/ ERK抑制剂AEZS-129和AEZS-136； disorazol Z产品AEZS-137和AEZS-138。
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Dimensional Fund Advisors Canada Inc | 6207 | 0.04% | -- | -- | 2019-07-31 |
| Susquehanna International Group, LLP | 67841 | 0.41% | 35490 | 109.70% | 2019-03-31 |
| Susquehanna Financial Group, LLLP | 67841 | 0.41% | 35490 | 109.70% | 2019-03-31 |
| Renaissance Technologies Corp | 110078 | 0.67% | 77000 | 232.78% | 2019-03-31 |
| Acadian Asset Management LLC | 167222 | 1.02% | 167222 | -- | 2019-03-31 |
| EAM Investors, LLC | 171019 | 1.04% | 171019 | -- | 2019-03-31 |
| ARONSON+JOHNSON+ORTIZ | 221614 | 1.35% | 221614 | -- | 2019-03-31 |
| J. Goldman & Co LP | 374000 | 2.27% | -623494 | -62.51% | 2019-03-31 |
| Morgan Stanley - Brokerage Accounts | 702277 | 4.27% | -5137 | -0.73% | 2019-03-31 |
| Hillsdale Investment Management Inc. | 63100 | 0.38% | 36900 | 140.84% | 2019-03-31 |
| BOOTHBAY FUND MANAGEMENT, LLC | 45853 | 0.28% | -- | -- | 2019-03-31 |
| BlackRock Fund Advisors | 41392 | 0.25% | -- | -- | 2019-07-31 |
| Russell Investments Canada Limited | 8384 | 0.05% | -968 | -10.35% | 2019-07-31 |
| Dimensional Fund Advisors LP | 18110 | 0.11% | -- | -- | 2019-07-31 |
| Fidelity Management & Research Company | 23853 | 0.15% | 3449 | 16.90% | 2019-07-31 |
| O'Shaughnessy Asset Management LLC | 25051 | 0.15% | 2520 | 11.18% | 2019-03-31 |
| GuideStone Capital Management, LLC | 26566 | 0.16% | -4015 | -13.13% | 2019-07-31 |
| Citadel Advisors Llc | 28493 | 0.17% | 28493 | -- | 2019-03-31 |
| Morgan Stanley Canada Ltd. | 31500 | 0.19% | -- | -- | 2019-03-31 |
| Virtu Financial LLC | 38480 | 0.23% | 38480 | -- | 2019-03-31 |
| S¨?nchez Casas Asesores EAFI | 8800 | 0.05% | -- | -- | 2019-07-31 |
| Deutsche Bank AG | 24000 | 0.15% | 1989 | 9.04% | 2018-12-31 |
| Anson Funds Management LP | 335781 | 2.04% | 335781 | -- | 2018-12-31 |
| Ardsley Advisory Partners | 25000 | 0.15% | 25000 | -- | 2018-12-31 |
| Morgan Stanley Smith Barney LLC | 10374 | 0.06% | 7573 | 270.37% | 2018-12-31 |
| JANE STREET GROUP, LLC | 10073 | 0.06% | 10073 | -- | 2018-12-31 |
| Hillsdale Investment Management | 26200 | 0.16% | 26200 | -- | 2019-05-31 |
| Bridgeway Capital Management, Inc | 111000 | 0.68% | 111000 | -- | 2018-12-31 |
| Guidestone Capital Management | 30581 | 0.19% | 30581 | -- | 2019-04-30 |
| Lake Street Risk Retention Group Inc | 111000 | 0.68% | 111000 | -- | 2018-12-31 |
| J.P. Morgan Securities Inc | 80900 | 0.49% | 1000 | 1.25% | 2018-09-30 |
| JPMorgan Chase & Co | 80900 | 0.49% | 1000 | 1.25% | 2018-09-30 |
| Truvestments Capital LLC | 4369 | 0.03% | 4369 | -- | 2018-09-30 |
| Vassalluzzo Scott J | 11438 | 0.07% | 11438 | -- | 2018-09-30 |
| UBS Group AG | 1036 | 0.01% | -12645 | -92.43% | 2018-12-31 |
| Ballew Advisors, Inc | 3000 | 0.02% | 3000 | -- | 2018-09-30 |
| Royal Bank of Canada | 601 | -- | 601 | -- | 2018-09-30 |
| Wells Fargo & Co | 800 | -- | -- | -- | 2018-09-30 |
| Citigroup Inc | 1000 | 0.01% | -- | -- | 2018-09-30 |
| Cutler Group LP | 900 | 0.01% | -- | -- | 2018-06-30 |
| Jnba Financial Advisors Inc | 91 | -- | -- | -- | 2018-06-30 |
| The Toronto-Dominion Bank | 438 | -- | 438 | -- | 2018-09-30 |
| Morgan Stanley & Co Inc | 215666 | 1.31% | 108400 | 101.06% | 2018-06-30 |
| Wells Fargo Advisors, LLC | 800 | -- | -- | -- | 2018-09-30 |
| UBS Securities LLC | 585 | -- | 585 | -- | 2018-06-30 |
| Bank of Montreal | 45 | -- | 1 | 2.27% | 2018-09-30 |
| Millennium Management LLC | -- | -- | -10553 | -100.00% | 2018-09-30 |
| Bank of America Corporation | 369 | -- | 359 | 3590.00% | 2018-03-31 |
| SIMPLEX TRADING, LLC | 276 | -- | -7061 | -96.24% | 2018-03-31 |
| Advisor Group, Inc. | 13 | -- | 13 | -- | 2018-03-31 |
| Ladenburg Thalmann Asset Management Inc | 3 | -- | -- | -- | 2018-06-30 |
| Merrill Lynch & Co Inc | 10 | -- | 10 | -- | 2018-06-30 |
| BMO Asset Management Inc | 44 | -- | -- | -- | 2018-06-30 |
| Stratos Wealth Partners, LTD | 16 | -- | 16 | -- | 2018-03-31 |
| Brandes Investment Partners & Co | 34000 | 0.21% | 34000 | -- | 2017-12-31 |
| TWO SIGMA SECURITIES, LLC | 16322 | 0.10% | -10293 | -38.67% | 2017-12-31 |
| Tower Research Capital LLC | 1397 | 0.01% | 1397 | -- | 2017-09-30 |
| Group One Trading, LP | 14670 | 0.09% | 14670 | -- | 2017-09-30 |
| Nine Chapters Capital Management LLC | 18500 | 0.11% | 18500 | -- | 2017-09-30 |
| Private Advisor Group, LLC | 20501 | 0.13% | 20501 | -- | 2017-09-30 |
| Springbok Capital Management, LLC | 10700 | 0.07% | 9700 | 970.00% | 2017-09-30 |
| DAVENPORT vermogensbeheer | 250 | -- | -- | -- | 2016-10-31 |
| Bt Alex Brown Inc | 11900 | 0.08% | -28900 | -70.83% | 2017-06-30 |
| KCG AMERICAS LLC | 18577 | 0.13% | 450 | 2.48% | 2017-06-30 |
| Sabby Management LLC | 67283 | 0.47% | 67283 | -- | 2017-06-30 |
| Metlife Securities Inc | 12 | -- | -- | -- | 2016-09-30 |
| Creative Planning Inc | 5015 | 0.05% | 4990 | 19960.00% | 2016-09-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| iShares Micro-Cap ETF | 41392 | 0.25% | -- | -- | 2019-07-30 |
| Bridgeway Ultra Small Company Fund | -- | -- | -111000 | -100.00% | 2019-03-31 |
| Maverick Fund FI | -- | -- | -8800 | -100.00% | 2019-07-31 |
| DFA Global Small Company Portfolio | 5 | -- | -- | -- | 2019-05-31 |
| NT Quality SCC Global Fund - Non-Lending | 1144 | 0.01% | 1144 | -- | 2019-06-30 |
| NT Quality SCC International Fund - NL | 1144 | 0.01% | 1144 | -- | 2019-06-30 |
| Hillsdale Canadian Small Cap Equity Fund | 1925 | 0.01% | 1925 | -- | 2018-12-31 |
| Brighthouse/Dimensional Intl Sm Cm Port | 2400 | 0.01% | -- | -- | 2019-06-30 |
| DFA World ex US Core Equity Portfolio | 2600 | 0.02% | -- | -- | 2019-05-31 |
| JHancock International Small Company Fd | 4400 | 0.03% | -- | -- | 2019-05-31 |
| DFA International Small Company Port | 4966 | 0.03% | -- | -- | 2019-06-30 |
| DFA International Small Cap Growth Portf | 5039 | 0.03% | -- | -- | 2019-06-30 |
| DFA TA World ex US Core Equity Port | 5500 | 0.03% | -- | -- | 2019-05-31 |
| DFA Canadian Vector Equity Fund | 6207 | 0.04% | -- | -- | 2019-05-31 |
| Russell Inv US Equity Pool | 8384 | 0.05% | -968 | -10.35% | 2019-05-31 |
| Hillsdale Global Small Cap Equity Fund | 17155 | 0.10% | 17155 | -- | 2018-12-31 |
| Fidelity | 23853 | 0.15% | 3449 | 16.90% | 2019-06-30 |
| GuideStone Funds Small Cap Equity Fund | 26566 | 0.16% | -4015 | -13.13% | 2019-06-30 |
| Hillsdale US Small Cap Equity Fund | -- | -- | -26200 | -100.00% | 2019-03-31 |
| Philip A. Theodore | Mr. Philip A. Theodore is Secretary & General Counsel at Medizone International, Inc. and Secretary, Chief Administrative Officer & SVP at �0�1�6�9terna Zentaris, Inc. Mr. Theodore was previously employed as Secretary, Vice President & General Counsel by Zep, Inc., VP-Corporate Development, Compliance & Legal by BioReliance Corp., General Counsel by CryoLife, Inc., General Counsel & Senior Vice President by John H. Harland Co., Secretary, Vice President & General Counsel by Serologicals Corp., and a Principal by King & Spalding LLP. He received his undergraduate degree from the University of Tennessee and a graduate degree from Uc College of Law. |
|---|---|
| James Clavijo | James Clavijo founded Capital View Partners, Inc. Presently, he is Chief Financial Officer of Real Brands, Inc., Chief Financial Officer of Ventumar SA, Chief Financial Officer for Tri-Source Pharma LLC and Chief Financial Officer at �0�1�6�9terna Zentaris, Inc. In the past James Clavijo was Chief Financial Officer for Gallery Industries, Inc., Chief Financial Officer for Guided Therapeutics, Inc., Chief Financial Officer & Managing Partner at Capital View Partners, Inc., Senior Vice President-Finance at BioNitrogen Holdings Corp., Chief Accounting Officer & Controller of Soligenix, Inc., Chief Financial Officer of Bluvision, Inc., Finance Manager at G4S Secure Solutions (USA), Inc., Chief Financial Officer of Cigarette Racing Team LLC and Corporate Controller at A Novo Broadband, Inc. James Clavijo received a graduate degree from Florida International University, an undergraduate degree from the University of Nebraska and an undergraduate degree from the University of Florida. |
| David A. Dodd | Mr. David A. Dodd is a Chief Executive Officer & Director at Medizone International, Inc., a Chairman at GeoVax Labs, Inc. and a Chief Executive Officer at Vaxygen Holdings LLC. He is on the Board of Directors at Medizone International, Inc. and �0�1�6�9terna Zentaris, Inc. Mr. Dodd was previously employed as a Chairman, President & Chief Executive Officer by BioReliance Corp., a Non-Executive Chairman by Stem Cell Sciences Plc, a President, Chief Executive Officer & Director by Serologicals Corp., a Chairman by Unimed Pharmaceuticals, Inc., a President & Chief Executive Officer by Solvay Pharmaceuticals, Inc., a Principal by Abbott Laboratories, a Chairman by American Foundation for Suicide Prevention, a Principal by Bristol-Myers Squibb Co., a Chairman by Georgia Bio, a Chief Executive Officer by RiversEdge BioVentures LLC, a Member-Management Board by Solvay SA, a Non-Executive Director by Stheno Corp., and a Principal by Wyeth-Ayerst Laboratories. He also served on the board at Sierra Leone Diamond Co. Ltd., ArunA Biomedical, Inc. and PNP Therapeutics, Inc. He received his undergraduate degree from Georgia State University and a graduate degree from Georgia State University. |
| Michael A. Cardiff | Michael A. Cardiff holds the position of Chief Executive Officer at Accelerents, Inc. He is also Member of Institute of Corporate Directors and on the board of 9 other companies. Mr. Cardiff previously occupied the position of Chief Executive Officer of Imperial Capital Group Ltd., President & Chief Executive Officer at Fincentric Corp., President & Chief Executive Officer for INEA Corp., National Vice President-General Business at SAP Canada, Inc., Senior Vice President for Infor (Canada) Ltd. and Executive Vice President-Financial Services at EDS Canada, Inc. |
| G�0�1�0�8rard Antoine Limoges | G�0�1�0�8rard Antoine Limoges is on the board of �0�1�6�9terna Zentaris, Inc., PRO Real Estate Investment Trust, Montreal Symphony Orchestra, Inc. and Hartco, Inc. and Member of Institute of Corporate Directors, Member of Ordre des administrateurs agr�0�1�0�8�0�1�0�8s du Qu�0�1�0�8bec, Member of Ordre des comptables professionnels agr�0�1�0�8�0�1�0�8s du Qu�0�1�0�8bec, Member of Chartered Professional Accountants of Quebec and Member of Canadian Institute of Chartered Accountants. Mr. Limoges previously held the position of Chairman of Genizon Biosciences, Inc., Deputy Chairman at Ernst & Young LLP (Canada), Chairman of Institut de Recherches Cliniques de Montr�0�1�0�8al and Chairman at Fellowship of Christian Athletes. G�0�1�0�8rard Antoine Limoges received an undergraduate degree from the University of Montr�0�1�0�8al. |
| Eckhard G. Guenther | Mr. Kenneth E. Newport is Chairman at Ottawa Life Sciences Council, Chairman at Ottawa Hospital Research Institute, and a Member at Institute of Corporate Directors. He is on the Board of Directors at �0�1�6�9terna Zentaris, Inc., Jennerex Biotherapeutics, Inc., and MedGenesis Therapeutix, Inc. Mr. Newport was previously employed as Independent Director by Nordion, Inc., Independent Director by OPMEDIC Group, Inc., Senior VP-Worldwide Business Development by Nordion, Inc., President by CroMedica International, Inc., Founding Member by Global Biomedical Capital Corp., Founding Member by Prime Trials Ltd., Founding Member by Azelon Pharmaceuticals, Inc., and Senior Vice President by Pinnacle Holdco Parent, Inc. He also served on the board at MDS Nordion, Inc. He received his undergraduate degree from The University of Waterloo and a graduate degree from The University of Waterloo. |
| Jonathan M. Pollack | Presently, Jonathan M. Pollack is President for JMP Fam Holdings, Inc., Chief Financial Officer & Secretary at KAB Distribution, Inc., Chief Financial Officer & Director at Babyzone.com, Inc. (a subsidiary of KAB Distribution, Inc.), Chief Financial Officer at AcuityAds Holdings, Inc. and Director-Lead & Director at Hanfeng Evergreen, Inc. Mr. Pollack is also on the board of 6 other companies. Mr. Pollack previously was Director & Executive Vice President at API Technologies Corp., Vice President & Founding Member at Violy Byorum & Partners, President for JMP Group, Inc. and Chief Financial Officer & Secretary at Kaboose, Inc. Mr. Pollack received a graduate degree from London School of Economics & Political Science and an undergraduate degree from McGill University. |
| Juergen H. L. Ernst | Juergen H. L. Ernst is on the board of �0�1�6�9terna Zentaris, Inc. (former Chairman) and Pharming Group NV. In the past he occupied the position of General Manager-Pharmaceutical Sector at Solvay SA and Head-Pharmaceutical Division at Kali-Chemie AG (a subsidiary of Solvay SA). Juergen H. L. Ernst received an MBA from Universit�0�1¤t zu K�0�1�0�9ln and an undergraduate degree from Harvard University. |
| H. B. Brent Norton | Founder of PreMD, Inc., H. B. Brent Norton is a businessperson who has been at the head of 5 different companies and currently is President, CEO, Director & Head-Investor Relations at this company and Venture Partner at Lumira Capital Investment Management, Inc. Dr. Norton is also on the board of �0�1�6�9terna Zentaris, Inc., Ontario Bioscience Industry Organization and Ortho Regenerative Technologies, Inc. (former President, Chief Executive Officer & Director) and Member of Advanced Technology Group USA, Inc. and Member of Richard Ivey School of Business Foundation. In the past he occupied the position of President & Chief Executive Officer at MedCurrent Corp., President, Chief Executive Officer & Director at Eyecarrot Innovations Corp., Treasurer & Director at Osler Bluff Ski Club Ltd., Chairman-Friends Project at The Canadian Institute for Advanced Research and Executive Director & Head-Investor Relations at Cotinga Pharmaceuticals, Inc. Dr. Norton received an MBA from the University of Western Ontario, a graduate degree from L'�0�1‰cole Polytechnique de Montr�0�1�0�8al and a doctorate from McGill University. |
| Leslie Auld | Presently, Leslie Auld is Chief Financial Officer & Senior Vice President of �0�1�6�9terna Zentaris, Inc. In her past career she occupied the position of CFO, Treasurer & Non-Independent Director at GeneNews Ltd., Controller of Helix BioPharma Corp., Chief Financial Officer of Citation Resources, Inc., Chief Financial Officer at CNP Therapeutics, Inc. and Senior Director-Finance at Luminex Molecular Diagnostics, Inc. Leslie Auld received an MBA from the University of Toronto and an undergraduate degree from the University of Western Ontario. |
| Robin Smith Hoke | Currently, Robin Smith Hoke is President & Chief Executive Officer at Leiter's Enterprises, Inc. Ms. Hoke is also on the board of �0�1�6�9terna Zentaris, Inc. In her past career she occupied the position of President-Commercial Operations & General Counsel at GeneraMedix Pharmaceuticals, Inc. and President at GeneraMedix, Inc. (a subsidiary of GeneraMedix Pharmaceuticals, Inc.), Partner at Kegler Brown Hill + Ritter Co. LPA, Senior Vice President-Global Business Development at Cardinal Health, Inc., In-House Counsel at Abbott Laboratories and Chairman for Concord Biosciences LLC. Robin Smith Hoke received an undergraduate degree from Michigan State University and a graduate degree from The Thomas M. Cooley Law School. |
| Carolyn Egbert | Carolyn Egbert is Non-Executive Chairman of �0�1�6�9terna Zentaris, Inc. Dr. Egbert is also Member of State Bar of Michigan and Member of The District of Columbia Bar. In the past Dr. Egbert held the position of Senior Executive VP-Global Ethics & Compliance at Solvay America, Inc. She received an undergraduate degree from George Washington University, a graduate degree from Seattle University, a doctorate from Georgetown University School of Medicine and a doctorate from Feinberg School of Medicine. |
| Jude Dinges | Mr. Jude Dinges is Chief Commercial Officer & Senior Vice President at �0�1�6�9terna Zentaris, Inc. |
| Carolyn Egbert | Dr. Richard Sachse is Senior VP, Chief Scientific & Medical Officer at �0�1�6�9terna Zentaris, Inc. and a Managing Director at AEterna Zentaris GmbH. Dr. Sachse was previously employed as Vice President-Global Translational Medicine by Boehringer Ingelheim GmbH and Head-Experimental Medicine by UCB SA. He received his undergraduate degree from Friedrich-Alexander University of Erlangen-Nuremberg and a doctorate degree from Friedrich-Alexander University of Erlangen-Nuremberg. |
| Eckhard G. Guenther | Eckhard G. Guenther is Vice President-Business Development for AEterna Zentaris GmbH and Vice President-Alliance Management at �0�1�6�9terna Zentaris, Inc. In the past Dr. Guenther held the position of Head-Research Coordination & Medicinal Chemistry at ASTA Medica AG. Eckhard G. Guenther received an undergraduate degree from Martin-Luther-Universit�0�1¤t Halle-Wittenberg. |
| Genevi�0�1¨ve Lemaire | Ms. Genevi�0�1¨ve Lemaire, CPA, is Chief Accounting Officer & Vice President-Finance at �0�1�6�9terna Zentaris, Inc. He received his undergraduate degree from the University of Sherbrooke. |
| Michael V. Ward | Presently, Michael V. Ward holds the position of President, CEO & Head-Media Relations at �0�1�6�9terna Zentaris, Inc. In his past career Mr. Ward was Senior Associate at K&R Law Group LLP, Partner at Outside GC LLC, Vice President-Corporate Development of AmerisourceBergen Corp., VP & Assistant General Counsel-Global Compliance at CDK Global, Inc., Vice President & General Counsel for ACCO Brands Corp., Chief Executive Officer at AEterna Zentaris GmbH, Secretary, Chief Legal & Compliance Officer at Sagent Pharmaceuticals, Inc., Secretary, Senior Vice President & General Counsel of Targus Group International, Inc. and Of Counsel at Arter & Hadden. Michael V. Ward received a graduate degree from Case Western Reserve University School of Law and an undergraduate degree from Albion College. |
| Michael Teifel | Founder of Munich Biotech AG, Michael Teifel is Vice President-Non Clinical Services at AEterna Zentaris GmbH and Vice President-Non Clinical Sciences at �0�1�6�9terna Zentaris, Inc. In his past career Dr. Teifel was Head-Pharmacology & Toxicology at Munich Biotech AG. He received a doctorate from Technische Universit�0�1¤t Darmstadt. |
| Nicola Ammer | Currently, Nicola Ammer holds the position of Chief Medical Officer & VP-Clinical Development at �0�1�6�9terna Zentaris, Inc. and Head-Clinical Development at AEterna Zentaris GmbH (a subsidiary of �0�1�6�9terna Zentaris, Inc.). She is also Head-Clinical Development at AEterna Zentaris GmbH. She previously occupied the position of Head-European Business Development Operations at Pierrel Research International AG. She received a graduate degree from the University of Duisburg-Essen. |
| Olaf Althaus | Olaf Althaus is Managing Director & General Manager at �0�1�6�9terna Zentaris, Inc. |
| Brian Garrison | Brian Garrison is SVP-Global Commercial Operations at �0�1�6�9terna Zentaris, Inc. In his past career Mr. Garrison held the position of Director-Oncology Reimbursement Marketing at Amgen, Inc. Mr. Garrison received an undergraduate degree from US Military Academy. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论